Vascular-targeted gene therapies have the potential to treat many of the leading causes of mortality in the western world. Unfortunately, these therapies have been ineffective due to poor vascular gene transfer. The use of alternative virus serotypes and the incorporation of vascular targeting ligands into vectors has resulted in only modest increases in vascular gene transfer. Adeno-associated virus (AAV) 1 has shown the most promise among the AAV vectors for the transduction of vascular endothelial cells. However, no straightforward smallscale purification strategy exists for AAV1 as it does for AAV2 making it difficult to quickly produce AAV1 vector for analysis. Here we have combined two AAV1 capsid protein modifications to enhance vascular gene transfer and allow easy purification of vector particles. Mosaic vector particles have been produced comprised of capsid proteins containing the well-characterized RGD4C modification to target integrins present on the vasculature, and capsid proteins containing a modification that permits metabolic biotinylation and efficient purification of mosaic particles by avidin affinity chromatography. We show that the RGD modification results in a 50-100-fold enhancement in endothelial cell gene transfer that is maintained in biotinylated mosaic AAV1 particles. These results suggest that mosaic virions hold significant promise for targeted gene delivery to the vasculature. Gene Therapy (2006) 13, 926-931
Adeno-associated virus (AAV) is a single-stranded DNA parvovirus that has many advantages as a gene transfer vehicle, including the ability to transduce both quiescent and dividing cells, the ability to promote long-term gene expression, and the fact that it has never been associated with human disease. 1 There are currently nine known serotypes of AAV. Of these, AAV type 2 (AAV2) has been the most widely studied and the most widely utilized as a gene delivery vector. However, while AAV2 has been used effectively to deliver genes into many different kinds of cells, 2 certain cell types remain refractory to AAV2-mediated gene transfer. [3] [4] [5] [6] These include cells of the vascular endothelium, 7 wherein there is a considerable interest in the ability to deliver genes for the treatment of a variety of diseases including arthrosclerosis, hypertension, myocardial ischemia, and cancer.
The genomes of the different AAV serotypes are similar, consisting of two open reading frames (ORFs) that are flanked by inverted terminal repeats (ITRs). 8 The viral structural proteins (VP1, VP2, and VP3) that comprise the AAV capsid are encoded by the right ORF. The first step in the viral infection process, cell attachment, is mediated by the interaction of specific regions of the capsid with cellular receptors and coreceptors. [9] [10] [11] [12] The primary attachment receptor for AAV2 has been identified as heparan sulfate proteoglycan (HSPG). 11 It has been suggested that HSPG present in the extracellular matrix of vascular cells may sequester AAV2 vectors away from the cell membrane and prevent transduction. 7 Therefore, a potential approach to increase transduction of vascular cells is the use of another AAV serotype that does not bind HSPG. Initial experiments have suggested that AAV1 and AAV5 serotype vectors may be better at transducing vascular cells than AAV2-based vectors. However, levels of gene transfer using these serotypes are still not very great (T O'Brien, NUI Galway, personal communication). 13 Therefore, alternative strategies are needed to promote more efficient gene delivery to the vasculature.
We have previously shown that the capsids of AAV vectors can be modified to contain small exogenous targeting peptides, and that the inclusion of these peptides can successfully expand the tropism of the modified vectors. 14, 16 When incorporated into an AAV2 capsid, a peptide encoding the 'RGD4C' motif, known to bind to cell-surface integrin receptors, was shown to significantly increase the ability of these vectors to transduce tumor cell lines characterized by low HSPG and high integrin expression. 15 Since integrins are also highly expressed on the vasculature and are even more highly expressed on damaged or proliferating vasculature characteristic of many disease states, we sought to investigate the ability of an RGD-modified AAV1 vector to transduce vascular endothelial cells.
We have shown that the region in the AAV1 capsid ORF following VP1 amino acid 590 will accept small epitope insertions and have previously engineered a small biotin acceptor peptide (BAP) into this position. 16 The RGD4C integrin targeting peptide (CDCRGDCFC) was inserted into the same position using unique restriction sites flanking the BAP insertion ( Figure 1 ). 14 RGD-modified AAV1 capsids were able to package vector genomes at levels indistinguishable from those of AAV1 vectors with unmodified or BAP-modified capsid proteins (Figure 2 ). Efficient transduction of vascular endothelial cells with AAV vectors has been problematic (unpublished observations). 7, 13 However, initial studies in our lab and the results of others have suggested that AAV1 transduces vascular endothelial cells significantly better than AAV2. 13 When RGDmodified AAV1 vectors were used to transduce HUVEC, we observed a dramatic increase in gene transfer efficiency compared to unmodified AAV1 (Figure 3a) . HeLa C12 cells that are also known to express avb3/5 integrins served as a positive control (Figure 3c ). An even greater increase in transduction (over 100-fold) was observed when RGD-modified AAV1 vectors were used to transduce human saphenous vein endothelial cells (HSaVEC) (Figure 3b ). Specificity for the targeted integrin receptor is provided by the observation that competition with excess RGD peptide, but not the control RGS peptide, reduced transduction of HSaVEC to the same level as unmodified AAV1 vector (Figure 3b ). Previous studies have suggested that in vitro transduction of endothelial cells correlates fairly well with subsequent in vivo experiments (T O'Brien, NUI Galway, personal communication). 13 However, in vitro experiments are carried out under static conditions, while gene transfer in vivo may need to be carried out under dynamic flow conditions that could reduce efficiency.
Furthermore, RGD-binding integrins are expressed on a wide variety of cells that could limit in vivo specificity. Thus, although the ability of the RGD capsid modification to increase vascular gene transfer in vivo remains to be determined, our findings here suggest that while AAV1 might be the best available AAV serotype vector for vascular gene transfer, significant barriers still exist that can be overcome by the capsid modification.
Although the use of alternative AAV serotypes and the development of rationally targeted AAV vectors have improved transduction, purification of these vectors has been problematic. While AAV2 vectors can be easily purified using heparin affinity resins, similar affinity systems do not exist for the other AAV serotypes or for Figure 1 Sequence of AAV1, BAP-modified AAV1, and RGD-modified AAV1 capsid proteins in the region of epitope insertion. Capsid proteins are encoded by pXR1, 17, 18 pXR1-Cap1.D590_591insBAP, 16 and pXR1-Cap1.D590_591insRGD, respectively. pXR1-Cap1.D590_591ins-BAP contains a 60 bp insertion encoding amino acids ASGLNDIFEAQKIEWHEALS between amino acid position 590 and 591 of the AAV VP1 capsid protein. Amino acids GLNDIFEAQKIEWHE make up the biotin acceptor peptide (BAP) motif that is site-specifically biotinylated at the lysine residue by biotin ligase. Five flanking amino acid (AS -ALS) residues were included in the construct to promote flexibility and display of the engineered BAP motif 14 and to provide restriction sites that were used to swap in an oligonucleotide encoding the RGD4C (CDCRGDCFC) motif to generate pXR1-Cap1.D590_591insRGD. Figure 1 . The DNA to be packaged was supplied by plasmid p-TrsSKcmvRFP (kindly provided by Dr Douglas McCarty, Ohio State University), a self-complementary AAV vector construct containing a CMV-driven dsRed2 red fluorescent protein (RFP) gene cassette. Biotin ligase activity for biotinylated vector production was provided by pEGFPBirA (kindly provided by Dr Michael Barry, Baylor College of Medicine) and cells were maintained in media supplemented with 2.5 nM biotin. To generate mosaic AAV1 virions containing modified capsid proteins at various ratios, helper constructs were mixed prior to transfection. Cell lysates were fractionated on iodixanol density gradients, 19 and vector genomes were quantified by real-time PCR assay. 20 Data are presented as the mean DRP titer from three separate preparations7standard deviation. There was no significant (Po0.05) difference between any of the samples.
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AAV2-based vectors that have been ablated of endogenous HSPG tropism. Although these vectors can be purified by equilibrium gradient density centrifugation and ion exchange column chromatography methods exist for some serotypes, 17, [22] [23] [24] [25] these methodologies are problematic, poorly scalable, and often not suited for routine laboratory use. We have previously described a process wherein BAP-modified AAV capsid proteins are metabolically biotinylated in packaging cells during vector production and have shown that biotinylated vectors produced in this manner can be quickly and efficiently purified using inexpensive commercially available monomeric avidin affinity columns. While this has allowed the purification of AAV vectors derived from serotype 1, 2, 3, 4, and 5 viruses, 16 the approach utilizes genetically modified capsid proteins with the BAP domain inserted into the same site we have determined to be optimal for the insertion of targeting epitopes. Although, it may be possible to genetically insert both targeting and BAP domains into the same capsid monomers at different sites, this approach would limit the flexibility of the system. Previous reports have shown that capsid mosaics can be generated by mixing different helper plasmids during the transfection stage of recombinant AAV production and that the resulting virions are not assembled homogeneously from the different capsid subunits but are instead composed of mixtures of subunits from each capsid type. 26, 27 To investigate the possibility of mixing different modified AAV1 capsid proteins, helper plasmids encoding either RGD-capsid modifications, or BAP-capsid modifications 16 were mixed pairwise at specific ratios of 1:9, 1:4, 1:1, 2:1, 4:1, and 9:1. Since these helper plasmids are identical except for the small genetic insertions with the AAV capsid protein gene and are equally efficient at replicating and packaging vector genomes, the resulting virions should be composed of subunits from each modified capsid gene used in the pairwise transfection mixture, and the ratio should determine the general composition of these virions. For nomenclature purposes, the mixtures are reported as a fraction in which the numerator represents percent of RGD-modified parental plasmid and the denominator represents the percent of BAP-modified parent. For example, a mosaic vector preparation consisting of 80% RGD-modified AAV1 plasmid and 20% BAP-modified AAV1 plasmid would be referred to as AAV1 RGD/BAP (80/20). Particle titers were determined from iodixanol-purified samples of mosaic virions, as well as unmodified AAV1 and non-mosaic RGD-modified or BAP-modified AAV1 samples, to verify effective DNA packaging. As shown in Figure 2 , particle titers were unaffected by varying the ratio of one type of modified capsid protein to the other.
Since, our ability to purify biotinylated AAV1 vectors by avidin affinity chromatography was based on particles containing BAP domain insertions in each capsid monomer, 16 we sought to determine if mosaic AAV1 vectors with fewer sites for enzymatic biotinylation per virion could still bind monomeric avidin and be purified in this manner. Therefore, crude vector samples with varying amounts of BAP-modified capsid proteins relative to RGD-modified capsid proteins were fractionated on iodixanol gradients and applied to monomeric avidin columns as described previously. 16 While particles comprised entirely of BAP-modified capsid proteins (AAV1-BAP) bound to the column very well, the samples with less BAP-modified capsid protein also bound effectively. As the percentage of BAP-modified helper plasmid decreased, binding affinity decreased slightly as evidenced by more particles being detected in the wash fractions (data not shown). Nevertheless, the majority of 
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MD Stachler and JS Bartlett recovered AAV particles for all mosaic vector combinations were found in the elution fraction (Figure 4 ). Even for virions that contained as little as 10% BAP-modified AAV1 capsid protein, greater than 64% of recovered vector was obtained in the elution fraction. It was also of interest to determine the minimal amount of the RGD4C peptide that needed to be displayed on the capsid surface to maintain enhanced gene transfer to endothelial cells. Therefore, mosaic vectors comprised of various amounts of RGD-modified capsid protein and BAP-modified capsid protein were purified by avidin affinity chromatography and used to transduce either HeLa C12 cells or HUVEC (Figure 5a and b, respectively). Interestingly, enhancement of transduction of both HeLa cells and HUVEC required a virion with a minimum 50% RGD-modified capsid protein. Increasing the percentage of the RGD-modified capsid proteins in the virion above 50% lead to further increases in gene transduction until a plateau was reached at about 90% RGD-modified capsid, where transduction was equivalent to a virion containing 100% RGD-modified capsid proteins. Enhanced transduction mediated by mosaic AAV1-RGD/BAP vectors was similar to that previously shown for 100% RGDmodified AAV1 vectors on vascular endothelial cells (Figure 3a and b) and is clearly evident in Figure 5c showing increased transduction of dsRed2 mediated by the mosaic AAV1-RGD4C/BAP (90/10) vector compared to the 100% BAP-modified AAV1 vector. Although it remains to be determined at a mechanistic level, it is presumed that the RGD-capsid modification is increasing transduction of endothelial cells by enhancing cellular uptake of vector particles. However, it is interesting to note that in addition to increasing the number of cells transduced, the RGD modification also seems to impart more rapid and robust transgene expression than seen with unmodified vectors ( Figure  5c , and unpublished observation). This discovery could become important in settings where the usual delay in the onset of AAV vector transgene expression is undesirable; for example, in vascular gene therapies directed against post-angioplasty restenosis, or in antiangiogenic cancer gene therapies, where quicker onset and higher levels of transgene expression may be valuable in increasing efficacy.
These data substantiate the assumption that mixing helper plasmids encoding different modified AAV1 capsid proteins during vector production results in the generation of mosaic vector particles. Since, these vectors were first purified by monomeric avidin affinity chromatography and then used to show enhanced endothelial cell transduction, the presence of both enzymatically biotinylated BAP-modified capsid proteins, and RGDmodified capsid proteins in the same vectors particle is confirmed. Furthermore, these results suggest that the number of targeting ligands on engineered vector particles may be of significant importance in maximizing vector targeting to alternative cellular receptors. Although, virion mosaicism has been utilized to alter vector tropism previously, 26, 27 mosaics comprised of two different modified capsid proteins have not been reported and the assumption has always been that the virion composition mirrors the ratio of the different helper plasmids used during vector AAV production. Our results suggest that virion composition can be biased by either purification or transduction requirements that rely on one of the two capsid monomers that make up the mosaic virion. By purifying mosaic particles by avidin affinity chromatography, we find that predicted capsid protein representation in mosaic virions is biased toward virions that contain a greater percentage of BAPmodified capsid protein monomers than RGD-modified capsid protein monomers. For instance, when virions were produced by transfection with a 2:1 ratio of helper plasmid encoding RGD-modified capsid protein to helper plasmid encoding BAP-modified capsid protein and purified by traditional methods, transduction was equivalent to virions produced by transfection with a 9:1 ratio of helper plasmid encoding RGD-modified capsid protein to helper plasmid encoding BAP-modified capsid protein and purified by avidin affinity chromatography (data not shown). It also seems likely that transduction mediated by mosaic virions might be biased toward virion compositions that contain a greater number of engineered capsid proteins that enable enhanced transduction. For example, in a mosaic virion that is predicted to contain an equal mixture of two different modified capsid proteins based on the transfection of equal molar ratios of helper plasmids during production, the observed gene transduction may be mediated by virions that favor one capsid protein over the other and may not be representative of the population as a whole. These findings may have important implications for both purification schemes and targeting strategies that rely on virion mosaicism.
In summary, since vascular-targeted therapies have the potential to treat diseases as varied as coronary artery disease and cancer, there has been widespread interest in developing gene delivery vectors capable of efficient vascular gene transfer. Unfortunately, most of the available vectors have yielded disappointing results. Building on previous work suggesting that particular AAV serotypes may be better at transducing endothelial cells, and work from our group on the genetic insertion of targeting ligands into AAV capsid proteins to alter vector tropism, [13] [14] [15] [16] we have developed a novel AAV1-based vector that transduces human endothelial cells (HUVEC and HSaVEC) cells significantly better than the untargeted parental virus. In addition, by creating mosaic virions, we have combined targeting modifications with those that permit efficient purification of vector particles and have overcome a significant limitation hampering the widespread application of alternative AAV vector serotypes. With optimization of capsid composition, purification strategies based on virion mosaics may be applicable to other AAV vectors as well.
